Sienna Biopharmaceuticals Inc SNNAQ
$0.00
Last Updated: Aug 20, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
Sienna Biopharmaceuticals Inc. Stock Analysis SNNAQ
United States Health Care Nano Cap Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of aesthetics and medical dermatology. The company is headquartered in Westlake Village, California and currently employs 13 full-time employees. The company went IPO on 2017-07-27. The firm is focused on bringing scientific innovations to patients whose lives remain burdened by their disease. Its lead candidate from its platform, SNA-120, is an inhibitor of Tropomyosin receptor kinase A (TrkA) for the treatment of psoriasis, as well as the associated pruritus (itch). The firm's second product candidate, SNA-125, is a dual Janus kinase 3 (JAK3)/TrkA inhibitor for the treatment of atopic dermatitis, psoriasis and the associated pruritus. In addition, the Company also offers SNA-001, a silver photo particle technology derived from its Topical Photoparticle Therapy platform.
Sienna Biopharmaceuticals Inc (SNNAQ) Chart
Financial Metrics & Statements of Sienna Biopharmaceuticals Inc (SNNAQ)
FAQ's for Sienna Biopharmaceuticals Inc (SNNAQ)
- As of August 2026, Sienna Biopharmaceuticals Inc SNNAQ is classified as not covered according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Sienna Biopharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Sienna Biopharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Sienna Biopharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Sienna Biopharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Sienna Biopharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Sienna Biopharmaceuticals Inc (SNNAQ)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
